A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 844
Last updated 2026-04-28
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Conditions
- Sjögren's Syndrome
Interventions
- DRUG
-
Dazodalibep
Dazodalibep will be given intravenously (IV).
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-25
- Primary Completion
- 2029-12-11
- Completion
- 2029-12-11
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Belgium
- Brazil
- Canada
- Chile
- Croatia
- France
- Germany
- Greece
- Hungary
- Israel
- Italy
- Japan
- Mexico
- New Zealand
- Peru
- Poland
- Portugal
- Serbia
- Slovenia
- South Korea
- Spain
- Taiwan
- United Kingdom
Study Locations
More Related Trials
-
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
NCT03247686 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
NCT02701985 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
NCT04186871 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
NCT05798117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525 ·Status: RECRUITING ·Phase: PHASE2
-
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome
NCT02843659 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
NCT05430854 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome
NCT01008982 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
NCT07041099 ·Status: RECRUITING ·Phase: PHASE1
-
Pilot Feasibility Study of a Sjögren's Syndrome Self-management App
NCT04653935 ·Status: UNKNOWN ·Phase: NA
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
NCT06977724 ·Status: RECRUITING ·Phase: PHASE1
-
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT05352919 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT04810754 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Baricitinib in Sjogren's Syndrome
NCT05016297 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
New Clinical End-points in Patients With Primary Sjögren's Syndrome
NCT05113004 ·Status: RECRUITING ·Phase: PHASE2
-
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
NCT03407482 ·Status: TERMINATED ·Phase: PHASE2
-
Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome
NCT06862284 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NCT06544330 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
NCT05591222 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
NCT04035668 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
NCT05504187 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome
NCT04931160 ·Status: RECRUITING ·Phase: NA
-
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
NCT06875960 ·Status: RECRUITING ·Phase: PHASE4